CLDX (Celldex Therapeutics) Other Gross PPE: $14.79 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
56 GF Score
Price $39.10
GF Value $2.43
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Other Gross PPE?

Celldex Therapeutics CLDX -3.31% 56 Other Gross PPE is $14.79 Mil as of Jun. 2026. GuruFocus rates CLDX with a GF Score™ of 56/100 and a GF Value™ of $2.43 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Celldex Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2026 was $14.79 Mil.

Celldex Therapeutics's quarterly Other Gross PPE declined from Dec. 2025 ($26.02 Mil) to Mar. 2026 ($9.41 Mil) but then increased from Mar. 2026 ($9.41 Mil) to Jun. 2026 ($14.79 Mil).

Celldex Therapeutics's annual Other Gross PPE increased from Dec. 2023 ($24.50 Mil) to Dec. 2024 ($27.60 Mil) but then declined from Dec. 2024 ($27.60 Mil) to Dec. 2025 ($26.02 Mil).

Celldex Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Other Gross PPE Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.65 25.42 24.50 27.60 26.02

Celldex Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.51 7.55 26.02 9.41 14.79
CLDX
56GF Score
Celldex Therapeutics Inc CLDX
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of $14.79 Mil mean?
Celldex Therapeutics (CLDX) has a Other Gross PPE of $14.79 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Other Gross PPE too high?
Celldex Therapeutics' current Other Gross PPE is $14.79 Mil. Overall, Celldex Therapeutics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Other Gross PPE compare to IRON and QURE?
Celldex Therapeutics' Other Gross PPE of $14.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Other Gross PPE is $14.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.43, compared to a current price of $39.10 — trading 1509.1% above its estimated fair value. The current Other Gross PPE is $14.79 Mil. Celldex Therapeutics' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Other Gross PPE is $14.79 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $39.10 is trading 1509.1% above its estimated GF Value™ of $2.43. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Other Gross PPE: $14.79 Mil
  • GF Value™: $2.43 vs. price of $39.10 (1509.1% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
56GF Score

Get the complete analysis for CLDX

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.10
Price
$2.43
GF Value